Bristol Myers Squibb (BMY) closed the most recent trading day at $51.60, moving +0.98% from the previous trading session. This change outpaced the S&P 500's 0.15% gain on the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.32%.The the stock of biopharmaceutical company has fallen by 6% in the past month, lagging the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65%.Analysts and investors alike will be keeping a close eye on the performance of Bristol Myers Squibb in its ...

In this articleBMYJNJJonathan Raa | Nurphoto | Getty ImagesThink a friend or colleague should be getting this newsletter? Share this link with them to sign up.Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J's drug is walking away with a notable edge over its rival.The FDA expanded the approvals of both therapies, allowing patients to use them as earlier lines of treatment for a type of blood ca ...

Bristol Myers Squibb (BMY) announced data from the cohorts of the KRYSTAL-1 study, evaluating the lung cancer drug Krazati (adagrasib) in combination with Erbitux (cetuximab), for the treatment of patients with previously treated KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC).KRYSTAL-1 is an open-label, multicenter, multiple expansion cohort phase I/II study to determine the safety and efficacy of Krazati in patients with advanced solid tumors that harbor a KRASG12C mutation.The pri ...

Bristol Myers Squibb (BMY) announced that the FDA approved a label expansion for chimeric antigen receptor (CAR) T cell immunotherapy Abecma. The therapy is now approved for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.It is to be noted that Abecma is being jointly developed and commercialized in the United States by Bristol My ...

April 6 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics.The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. Long-term data of the drug reinforced the findings that were seen in previous short-term studies, the company sa ...

With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one’s buck. For new investors seeking reasonable valuations and overlooked long-term growth drivers, the biotech scene is worth considering.With the rise of diabetes drugs, whose benefits may extend beyond losing weight (a recent study shed light on its ability to help treat Parkinson’s Disease potentially), the biotech indu ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this biopharmaceutical company have returned -2.3% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has lost 3.5% over this period. Now the key question is: Where could the stock be headed ...

Bristol Myers Squibb (BMY) announced that the European Commission (EC) has approved a label expansion of Reblozyl (luspatercept).The EC expanded the drug’s label to include the first-line treatment of adult patients with transfusion-dependent anemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS). The approval of Reblozyl covers all European Union (EU) member states.The latest approval is based on results of the late-stage COMMANDS study, wherein Reblozyl demonstrated superior eff ...

monsitj Bristol-Myers Squibb, Inc. (NYSE:BMY) is in the health care sector and in the pharmaceutical industry. While not a factor in my analysis of the company, BMY is expected to have 2024 annual revenue of $45.85B and annual earnings per share of $6.83. BMY is also yielding a safe 4.43%. In this article I will outline why I think BMY is a speculative buy at this price. It is speculative because not all of my preferred parameters are in place yet as I will outline in the article. My investment thesis w ...

Core Insights - Three companies in the pharmaceuticals and healthcare sectors present significant investment opportunities due to their strategic growth initiatives and market positioning [1][2] Group 1: Bristol-Myers Squibb (BMY) - Bristol-Myers Squibb has enhanced its growth profile through strategic acquisitions, including RayzeBio, Mirati Therapeutics, and Karuna Therapeutics, which provide advanced platforms and pipeline assets [3] - The acquisition of Karuna Therapeutics supports the potential for multi-billion-dollar sales from KarXT, aimed at treating schizophrenia and Alzheimer's psychosis [3] - Strategic alliances, such as the one with SystImmune, provide unique technology and oncology resources, enhancing the company's market capabilities [4] Group 2: Walgreens Boots Alliance (WBA) - Walgreens Boots Alliance reported an 8.7% year-over-year increase in pharmacy comp sales in Q2 2024, driven by prescription volume growth and brand inflation [5] - The acquisition of Summit Health and collaboration with VillageMD have strengthened Walgreens Boots Alliance's healthcare service offerings [5][6] - Boots UK demonstrated resilience with a 3.2% year-over-year sales increase, supported by strategic initiatives and market share growth [6] Group 3: CVS Health (CVS) - CVS Health achieved $93.8 billion in consolidated Q4 revenues, reflecting an 11.9% year-over-year growth, and $357.8 billion in consolidated revenue for 2023, a 10.9% increase [7] - The Healthcare Benefits division reported approximately $27 billion in Q4 revenues, a significant rise of over 16% year-over-year, showcasing the segment's adaptability [7][8] - The Health Services segment generated over $49 billion in Q4 sales, indicating a growth of over 12% year-over-year, driven by strong pharmacy services and strategic acquisitions [8]